Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
about
Circulating glioma biomarkersA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesIdentification of potent Yes1 kinase inhibitors using a library screening approach.Antiangiogenic therapy for glioblastoma.Antiangiogenic therapy for glioblastoma: current status and future prospects.Glial progenitors as targets for transformation in glioma.The challenges and the promise of molecular targeted therapy in malignant gliomas.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.An update in the use of antibodies to treat glioblastoma multiforme.Anti-vascular endothelial growth factor therapy for malignant glioma.Tumor-stromal interactions in breast tumor progression--significance of histological heterogeneity of tumor-stromal fibroblasts.Targeted therapy in gliomas.Recent advances in targeted therapy for glioblastoma.Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).Design considerations for dose-expansion cohorts in phase I trialsQuantitative perfusion imaging of neoplastic liver lesions: A multi-institution study.
P2860
Q26830329-D02C1148-29D6-4765-B9FC-70482558C58FQ26851160-3E100C0F-186F-405D-96DB-1EB747CD4CFEQ26862516-F408DC02-7487-433F-B67A-3C2AD9F50899Q31119738-2CD8ABE1-307B-480D-9955-752236F0DEA0Q34145245-A3E07655-7B14-401F-B148-1EA70C8ACCA1Q34523319-651E1CD2-9B49-40C6-86D5-FB178BD7C482Q34735661-1C3A1F82-1624-4526-8CE4-487DD88FA281Q35214534-6F8FC3C1-8916-4D6F-A0AF-45BDDEF9B858Q35434188-9899618F-B742-47FA-BEF3-63ABEA948103Q35895174-6F706FD8-96F9-4B42-821C-3186270E78A3Q37329927-A2B711A6-62CE-4F24-A10E-E49546783C02Q37434674-DEF66035-DE8A-4F21-860E-045F3330B502Q38072443-5D460B38-A46C-4BC3-A85E-D5C83C8212B7Q38186656-A43E1D0F-E35D-4F71-B90D-252DD9457860Q38539386-5B2808A5-2315-42B3-8CF6-8778DAA577E2Q38694765-F8448AB9-E76E-4E8A-8A5D-11E255D9E6E9Q38922319-E86FD2E9-6E75-4007-ACBB-14B59B77A656Q38996431-E2C80C88-AD4F-4D25-A289-F3E5AF0A6A61Q39344380-69D438B2-B8A1-4BF3-9C65-4FCB4CECC98BQ40705444-55985724-2A2D-470C-9D76-1A8FDDFB879EQ41895594-B90F60EA-7360-464E-8C32-92443140C6B6Q55336880-A13F94B2-324B-490B-8332-E77DF9B724A9
P2860
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@ast
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@en
type
label
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@ast
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@en
prefLabel
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@ast
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@en
P2093
P2860
P1476
Phase I study of AEE788, a nov ...... current glioblastoma patients.
@en
P2093
Charles A Conrad
Clifford DiLea
Jerry Huang
Kenneth D Aldape
Margaret Dugan
Michael D Prados
Paul Mischel
Timothy Cloughesy
W K Alfred Yung
P2860
P2888
P304
P356
10.1007/S00280-012-1854-6
P577
2012-03-07T00:00:00Z